Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 20/20 | 0.62 |
| ▸ | CTSL | P07711 | 11/20 | 0.53 |
| ▸ | CTSS | P25774 | 8/20 | 0.53 |
| ▸ | CTSB | P07858 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7664851 | 0.91 | CTSK (0.73) | CTSKCTSLCTSSCTSB | |
| SCHEMBL7664368 | 0.89 | CTSK (0.61) | CTSKCTSLCTSSCTSB | |
| SCHEMBL7664898 | 0.86 | CTSK (0.66) | CTSKCTSLCTSSCTSB | |
| SCHEMBL7672779 | 0.85 | CTSK (0.57) | CTSKCTSLCTSSCTSB | |
| SCHEMBL7671047 | 0.85 | CTSK (0.62) | CTSKCTSLCTSSCTSB | |
| SCHEMBL7670775 | 0.85 | DRD4 (0.46) | CTSKCTSLCTSS | |
| SCHEMBL7660322 | 0.83 | CTSK (0.43) | CTSKCTSLCTSSCTSB | |
| SCHEMBL7670995 | 0.81 | KDM4E (0.41) | CTSK | |
| SCHEMBL7670989 | 0.81 | KDM4E (0.41) | CTSK | |
| SCHEMBL7664379 | 0.81 | CTSK (0.63) | CTSKCTSLCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020082426-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-06-27 | — | — | US | claimed |
| EP-1086083-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2001-09-26 | — | — | EP | claimed |
| EP-1086083-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-03-28 | — | — | EP | claimed |
| WO-1999064399-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-16 | — | — | WO | claimed |
| US-20020082426-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-06-27 | — | — | US | disclosed |
| EP-1086083-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-1086083-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999064399-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082426-A1 | Protease inhibitors | CTSK, CTSZ, CTSB | CTSK 1/4885CTSL 6/4885CTSS 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.